Pathways of coagulation/fibrinolysis activation in malignancy.
about
Usefulness of 4D-CTA in the detection of cerebral dural sinus occlusion or stenosis with collateral pathways.Interleukin 12 induces activation of fibrinolysis and coagulation in humans.Cancer treatment with inhibitors of urokinase-type plasminogen activator and plasmin.The hemostatic system and angiogenesis in malignancy.MDA-9/syntenin is essential for factor VIIa-induced signaling, migration, and metastasis in melanoma cellsAnalysis of Cynandione A's Anti-Ischemic Stroke Effects from Pathways and Protein-Protein Interactome.Regulation of fibrin deposition by malignant mesotheliomaRationale for clinical trials of coagulation: reactive drugs in hepatocellular carcinoma.Thrombin enhances the adhesion and migration of human colon adenocarcinoma cells via increased beta 3-integrin expression on the tumour cell surface and their inhibition by the snake venom peptide, rhodostominAnti-thrombotics in thrombosis and cancer.The risk of a second cancer after hospitalisation for venous thromboembolism.Role of thrombin receptor in breast cancer invasiveness.Hypercoagulability and lung cancer.The prognostic value of D-dimer levels in metastatic osteosarcoma patients treated with second-line chemotherapy.The impact of thromboprophylaxis on cancer survival: focus on pancreatic cancer.Thrombin expression in prostate: a novel finding.Predisposing factors to post-operative adhesion development.Protein Z/protein Z-dependent protease inhibitor system in loco in human gastric cancerPlatelets and cancer angiogenesis nexus.Quantification of protein Z expression in lung adenocarcinoma tissues and cells.Venous thromboembolism and risk of cancer in patients with rheumatoid arthritis.Activation of coagulation and fibrinolysis during reconstructive microsurgery in patients with cancer.Clinical significance of coagulation assays in metastatic pancreatic adenocarcinoma.Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study.A Novel Clinical Factor, D-Dimer Platelet Multiplication, May Predict Postoperative Recurrence and Prognosis for Patients with Cholangiocarcinoma.Reversion of primary hyperfibrinogenolysis in patients with hormone-refractory prostate cancer using docetaxel.Analysis of haemostasis biomarkers in patients with advanced stage lung cancer during hypofractionated radiotherapy treatment.
P2860
Q30428096-B7DCE2AA-805B-4343-9268-210F2F6DD46AQ33181606-3B735902-589C-4371-9003-E24974483446Q34075065-6F999259-00CB-469E-B24F-F0BE2F994DC8Q34425462-C033BD63-75D4-4FAC-BEE6-F6400B1A9995Q35055504-46F037E1-5C8F-4D2E-89D0-9165B4C41F27Q35587151-0BC12178-875E-4073-8A0B-E25734C01C6BQ35795542-C8391C0B-D6B4-44F3-94FE-F307C9DABEABQ35879110-0C46E3F1-AF34-468E-9405-2ECB9C01AB56Q36134295-DDDC5C17-2B58-4206-9585-1789B2FDF3DAQ36429503-62EC0C78-BDC4-412B-B746-DA0E2366FF89Q36615418-4DB20854-84E3-43A7-BAB9-515D5BBB7ED4Q36618228-48BA817E-D136-41C9-BDD9-C977A6AD7378Q37188554-F708098E-6766-462C-89CE-3B9D2D82DB9FQ37662270-06BE3FEF-554C-442A-882D-36A4E2021C86Q37866790-758A1407-763D-4020-B399-6680F7DC0E99Q38413090-8CBF1FFC-B9B7-4836-8C7A-E4FB1201F504Q38455443-4B70D90D-DDA7-45CA-8902-65A748208126Q38622983-FB366143-CB2D-4F5F-A647-E2652CF88BABQ38691783-82248C1E-06FC-4BCE-A903-7068485CA736Q38755411-A90AFFE7-F37C-4958-A7A4-D2F141CC60FBQ40039414-583B2A77-C954-4717-AA47-45BB384483CEQ43700708-549C5B32-1BF3-41BC-8B3B-F0D0E4BDBA59Q45377635-18BAEE40-9E69-4054-9827-D303BEFD2CB4Q47794474-E97D3B39-A21C-4649-B5E2-559363579462Q52858939-3A9186B1-3206-426F-B87D-0C237083BBB5Q54023173-E0F1E8A2-3426-4117-8AC1-978AABE7CA60Q55047973-2EE6B1B2-AB23-4B41-BE8D-7C9F64B0DE5D
P2860
Pathways of coagulation/fibrinolysis activation in malignancy.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
Pathways of coagulation/fibrinolysis activation in malignancy.
@ast
Pathways of coagulation/fibrinolysis activation in malignancy.
@en
type
label
Pathways of coagulation/fibrinolysis activation in malignancy.
@ast
Pathways of coagulation/fibrinolysis activation in malignancy.
@en
prefLabel
Pathways of coagulation/fibrinolysis activation in malignancy.
@ast
Pathways of coagulation/fibrinolysis activation in malignancy.
@en
P2093
P356
P1476
Pathways of coagulation/fibrinolysis activation in malignancy
@en
P2093
Costantini V
Ornstein DL
Zacharski LR
P304
P356
10.1055/S-2007-1002415
P577
1992-01-01T00:00:00Z